ZA200108417B - Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy. - Google Patents

Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy.

Info

Publication number
ZA200108417B
ZA200108417B ZA200108417A ZA200108417A ZA200108417B ZA 200108417 B ZA200108417 B ZA 200108417B ZA 200108417 A ZA200108417 A ZA 200108417A ZA 200108417 A ZA200108417 A ZA 200108417A ZA 200108417 B ZA200108417 B ZA 200108417B
Authority
ZA
South Africa
Prior art keywords
disease
therapy
combination
degrading enzyme
synthesis inhibitors
Prior art date
Application number
ZA200108417A
Other languages
English (en)
Inventor
Raymond A Dwek
Frances M Platt
Mylvaganam Jeyakumar
Terence D Butters
David Priestman
Original Assignee
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd filed Critical Oxford Glycosciences Uk Ltd
Publication of ZA200108417B publication Critical patent/ZA200108417B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200108417A 1999-04-20 2001-10-12 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy. ZA200108417B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9909066.4A GB9909066D0 (en) 1999-04-20 1999-04-20 Therapies

Publications (1)

Publication Number Publication Date
ZA200108417B true ZA200108417B (en) 2003-03-26

Family

ID=10851917

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108417A ZA200108417B (en) 1999-04-20 2001-10-12 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy.

Country Status (15)

Country Link
US (2) US20020142985A1 (xx)
EP (2) EP1171128B1 (xx)
JP (1) JP4633939B2 (xx)
AT (1) ATE243037T1 (xx)
AU (1) AU775842B2 (xx)
BR (1) BR0009913A (xx)
CA (1) CA2368812C (xx)
DE (1) DE60003409T2 (xx)
ES (1) ES2200865T3 (xx)
GB (1) GB9909066D0 (xx)
IL (1) IL140379A (xx)
MX (1) MXPA01010707A (xx)
NO (1) NO329035B1 (xx)
WO (1) WO2000062779A1 (xx)
ZA (1) ZA200108417B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1196190B1 (en) * 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
GB0006539D0 (en) * 2000-03-17 2000-05-10 Oxford Glycosciences Uk Ltd Therapies
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2002241853A1 (en) * 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
US20080185293A1 (en) * 2002-03-27 2008-08-07 Giselher Klose Method and Apparatus for Decontamination of Fluid with One or More High Purity Electrodes
BR0313808A (pt) * 2002-08-27 2005-07-05 Nestle Sa Prevenção ou tratamento de lesão de tecidos epiteliais ou queda de cabelo
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US7429460B2 (en) 2003-01-15 2008-09-30 Yeda Research And Development Co., Ltd. Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US7884115B2 (en) * 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
KR101787939B1 (ko) 2006-01-24 2017-10-18 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
EP1986612B1 (en) 2006-02-07 2012-09-12 Shire Human Genetic Therapies, Inc. Stabilized composition of glucocerebrosidase
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
WO2012001641A1 (en) * 2010-06-30 2012-01-05 Actelion Pharmaceuticals Ltd Stable pharmaceutical compositions
MX361231B (es) 2012-03-02 2018-11-30 Shire Human Genetic Therapies Composiciones y usos de las mismas para tratar la enfermedad de gaucher tipo iii.
US20150118221A1 (en) * 2012-05-08 2015-04-30 The John Hopkins University Compositions and methods for treating cardiac hypertrophy
WO2014005103A2 (en) 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en) * 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
GB201407837D0 (en) * 2014-05-02 2014-06-18 Cambridge Entpr Ltd Methods of cancer therapy
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7445251B2 (ja) * 2017-12-28 2024-03-07 国立大学法人 熊本大学 アルツハイマー病予防剤又は治療剤、アルツハイマー病予防用又は治療用組成物、及び方法
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
US20230140216A1 (en) 2020-02-03 2023-05-04 Gain Therapeutics Sa Combination therapy for treating mps1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182767A (en) * 1876-10-03 Improvement in window-screens
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US5151519A (en) 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
DE69735669T2 (de) * 1996-07-15 2007-03-29 Macrozyme Dnm B.V. Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
EP1196190B1 (en) * 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Also Published As

Publication number Publication date
US20050075305A1 (en) 2005-04-07
ES2200865T3 (es) 2004-03-16
CA2368812A1 (en) 2000-10-26
NO20015111D0 (no) 2001-10-19
JP2002542194A (ja) 2002-12-10
DE60003409T2 (de) 2004-05-19
IL140379A0 (en) 2002-02-10
AU775842B2 (en) 2004-08-19
US7348000B2 (en) 2008-03-25
MXPA01010707A (es) 2002-08-20
BR0009913A (pt) 2002-01-08
GB9909066D0 (en) 1999-06-16
CA2368812C (en) 2009-06-30
DE60003409D1 (de) 2003-07-24
NO329035B1 (no) 2010-08-02
JP4633939B2 (ja) 2011-02-16
AU4133200A (en) 2000-11-02
ATE243037T1 (de) 2003-07-15
NO20015111L (no) 2001-12-12
EP1171128B1 (en) 2003-06-18
IL140379A (en) 2006-09-05
EP1171128A1 (en) 2002-01-16
EP1321143A1 (en) 2003-06-25
US20020142985A1 (en) 2002-10-03
WO2000062779A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
IL140379A0 (en) Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
PT1007043E (pt) Metodo para o tratamento de doencas de armazeamento lisossomico com envolvimentode cns
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU2003226014A8 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
GB0108592D0 (en) Therapeutic agents
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
MY135838A (en) Methods for the treatment of mental disorders
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
EE04176B1 (et) Selegiliini kasutamine epileptiliste haiguste raviks mõeldud ravimpreparaatide valmistamiseks
MY124089A (en) Use of cetirizine for preventing the onset of asthma
AUPS185602A0 (en) Treatment of alzheimer's disease (ad)